DivestmentJul 29, 2026, 06:13 AM
Clarivate to Divest LS&H Segment; Q2 Net Loss $(268.6)M, Impairment $221.7M
AI Summary
Clarivate announced a definitive agreement in July 2026 to sell its Life Sciences & Healthcare segment, leading to a significant non-cash goodwill impairment charge of $221.7M in the second quarter of 2026. The company reported a net loss of $(268.6)M for the quarter and total revenues of $587.3M. For the six months ended June 30, 2026, Clarivate generated $233.4M in net cash from operating activities and repurchased $18.1M of ordinary shares.
Key Highlights
- Entered into a definitive agreement in July 2026 to sell the Life Sciences & Healthcare segment.
- Recognized a $221.7M non-cash goodwill impairment charge for the LS&H reporting unit.
- Reported a net loss of $(268.6)M for the three months ended June 30, 2026.
- Total revenues for the three months ended June 30, 2026, were $587.3M.
- Net cash provided by operating activities was $233.4M for the six months ended June 30, 2026.
- Repurchased 7.0 million ordinary shares for $18.1M during the six months.
- Total assets decreased to $10,486.1M as of June 30, 2026, from $11,069.4M.
- Long-term debt decreased to $4,209.3M as of June 30, 2026, from $4,321.5M.
Price Impact
More from CLVT